Medtronic isn’t afraid of Wegovy’s potential to disrupt

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with an update on biotech’s silly season, a looming showdown in Washington, and the latest twist in the Ozempic panic. This newsletter is taking the next couple days off in the spirit of the holiday, but we’ll be back in your inbox Monday morning.

The need-to-know this morning
• Freeline Therapeutics, a cash-strapped developer of gene therapies, is being taken private in a transaction with Syncona Ltd., a life sciences investment fund. The acquisition, which values Freeline at $28 million, will enable the company to continue developing a gene therapy for Gaucher disease.
• Evelo Biosciences has shut down as a result of multiple drug-development setbacks and insurmountable financial troubles.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In